Suramin inhibits cell proliferation in ovarian and cervical cancer by downregulating heparanase expression

Cancer Cell International

JinQuan Cui²  MingHua Cao³  Bo Yuan²  MingZhu Zhao³  HongJie Qu²  HuaLi Li¹  HuaPing Li³ 

[1] Department of medicine laboratory, The Food and Drug Administration of pingdingshan, Labor Road, Pingdingshan, China;Department of Gynaecology and Obstetrics, The Second Affiliated Hospital of Zhengzhou University, Longitude eighth Road, Zhengzhou, China;Department of Gynaecology and Obstetrics, Punan Hospital of Pudong District, South Pudong Road, Shanghai, China

关键词: Cervical cancer;    Ovarian cancer;    Heparanase;    Inhibition;    Suramin;   

Others  :  1219357
DOI  :  10.1186/s12935-015-0196-y

 received in 2014-07-28, accepted in 2015-04-12,  发布年份 2015

【 摘 要 】

Background

Aberrant expression of heparanase (Hpa) is associated with apoor prognosis in ovarian and cervical cancer patients. Inhibitors of Hpa can prevent the growth and metastasis of malignant tumor cells, and suramin may be such a compound that has strong anti-proliferative effects on several kinds of cancer cells. We have therefore tested whether the growth inhibiting effect of suramin on ovarian and cervical cancer cells is due to downregulation of Hpa expression.

Results

Suramin at 300–600 μg/ml significantly inhibited HO-8910 PM and HeLa cell growth at 24 h, in both a time-dependent and dose-dependent manner, with an IC₅₀ of 320 μg/ml and 475 μg/ml, respectively. Suramin at 300 μg/ml significantly decreased the expression of Hpa mRNA (P < 0.005) and protein (P < 0.005) in both HO-8910 PM and HeLa cells at 48 h.

Conclusions

The inhibitory effect of suramin on Hpa enzyme may be due to downregulating of its expression in cancer cells. These findings confirm the importance of Hpa in tumor growth and the potential clinical application of Hpa inhibitors in the treatment of ovarian and cervical cancer.

【 授权许可】

   
2015 Li et al.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Siegel R, Naishadham D, Jemal A. Cancer statistics. 2012. CA Cancer J Clin. 2012; 62:10-29.
• [2]Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY et al.. A Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012; 30:372-9.
• [3]Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H et al.. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011; 365:2473-83.
• [4]Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G et al.. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365:2484-96.
• [5]Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A et al.. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012; 30:2039-45.
• [6]Suh DH, Kim JW, Kim K, Kim HJ, Lee KH. Major clinical research advances in gynecologic cancer in 2012. J Gynecol Oncol. 2013; 24:66-82.
• [7]Eskander RN, Tewari KS. Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol. 2014; 25:249-59.
• [8]Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, Vlodavsky I. Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J. 2010; 277:3890-903.
• [9]Roy M, Marchetti D. Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem. 2009; 106:200-9.
• [10]Purushothaman A, Uyama T, Kobayashi F, Yamada S, Sugahara K, Rapraeger AC et al.. Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis. Blood. 2010; 115:2449-57.
• [11]Cohen I, Pappo O, Elkin M, San T, Bar-Shavit R, Hazan R et al.. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int J Cancer. 2006; 118:1609-17.
• [12]Ginath S, Menczer J, Friedmann Y, Aingorn H, Aviv A, Tajima K et al.. Expression of heparanase, Mdm2, and erbB2 in ovarian cancer. Int J Oncol. 2001; 18:1133-44.
• [13]Kodama J, Shinyo Y, Hashen G, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase messenger RNA expression in epithelial ovarian tumor. Int J Mol Med. 2003; 12:961-4.
• [14]Zeng C, Ke ZF, Luo WR, Yao YH, Hu XR, Jie W et al.. Heparanase overexpression participates in tumor growth of cervical cancer in vitro and in vivo. Med Oncol. 2013; 30:403.
• [15]Davidson B, Shafat I, Risberg B, Ilan N, Trope’ CG, Vlodavsky I et al.. Heparanase expression correlates with poor survival in metastatic ovarian carcinoma. Gynecol Oncol. 2007; 104:311-9.
• [16]Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol. 2003; 14:1505-10.
• [17]Zhang W, Yang HC, Wang Q, Yang ZJ, Chen H, Wang SM et al.. Clinical value of combined detection of serum matrix metalloproteinase-9, heparanase, and cathepsin for determining ovarian cancer invasion and metastasis. Anticancer Res. 2011; 31:3423-8.
• [18]Basappa J, Murugan S, Kavitha CV, Purushothaman A, Nevin KG, Sugahara K et al.. A small oxazine compound as an anti-tumor agent: a novel pyranoside mimetic that binds to VEGF, HB-EGF, and TNF-alpha. Cancer Lett. 2010; 297:231-43.
• [19]Kudchadkar R, Gonzalez R, Lewis KD. PI-88: a novel inhibitor of angiogenesis. Expert Opin Investig Drugs. 2008; 17:1769-76.
• [20]Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P et al.. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010; 21:1302-7.
• [21]Taylor CW, Lui R, Fanta P, Salmon SE. Effects of suramin on in vitro growth of fresh human tumors. J Natl Cancer Inst. 1992; 84:489-94.
• [22]Lam ET, Au JL, Otterson GA, Guillaume Wientjes M, Chen L, Shen T et al.. Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemother Pharmacol. 2010; 66:1019-29.
• [23]Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M et al.. Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res. 1998; 4:1429-36.
• [24]Larsen AK. Suramin: an anticancer drug with unique biological effects. Cancer Chemother Pharmacol. 1993; 32:96-8.
• [25]Nakajima M, De Chavigny A, Johnson CE, Hamada J, Stein CA, Nicolson GL. Suramin. A potent inhibitor of melanoma heparanase and invasion. J Biol Chem. 1991; 266:9661-6.
• [26]Firsching A, Nickel P, Mora P, Allolio B. Antiproliferative and angiostatic activity of suramin analogues. Cancer Res. 1995; 55:4957-61.
• [27]Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growthand metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res. 1999; 59:3433-41.
• [28]Marchetti D, Reiland J, Erwin B, Roy M. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues. Int J Cancer. 2003; 104:167-74.
• [29]Sadashiva MP, Basappa S, Nanjundaswamy S, Li F, Manu KA, Sengottuvelan M et al.. Anti-cancer activity of novel dibenzo[b, f]azepine tethered isoxazoline derivatives. BMC Chem Biol. 2012; 12:5. BioMed Central Full Text
• [30]Kaur M, Reed E, Sartor O, Dahut W, Figg WD. Suramin’s development: what did we learn? Invest New Drugs. 2002; 20:209-19.
• [31]Reed E, Cooper MR, LaRocca RV, Bostick-Bruton F, Myers CE. Suramin in advanced platinum-resistant ovarian cancer. Eur J Cancer. 1992; 28A:864-6.
• [32]Kikuchi Y, Hirata J, Hisano A, Tode T, Kita T, Nagata I. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum(II). Gynecol Oncol. 1995; 58:11-5.
• [33]La Rocca RV, Meer J, Gilliatt RW, Stein CA, Cassidy J, Myers CE et al.. Suramin-induced polyneuropathy. Neurology. 1990; 40:954-60.
• [34]Kobayashi K, Weiss RE, Vogelzang NJ, Vokes EE, Janisch L, Ratain MJ. Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996; 78:2411-20.
• [35]Figg WD, Cooper MR, Thibault A, Headlee D, Humphrey J, Bergan RC et al.. Acute renal toxicity associated with suramin in the treatment of prostate cancer. Cancer. 1994; 74:1612-4.
• [36]Song S, Wientjes MG, Gan Y, Au JL. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 2000; 97:8658-63.
• [37]Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J et al.. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2006; 24(27):4384-90.
• [38]Lustberg MB, Pant S, Ruppert AS, Shen T, Wei Y, Chen L et al.. Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes. Cancer Chemother Pharmacol. 2012; 70:49-56.
• [39]Horiuchi KY, Eason MM, Ferry JJ, Planck JL, Walsh CP, Smith RF et al.. Assay development for histone methyltransferases. Assay Drug Dev Technol. 2013; 11:227-36.
• [40]Botta G, De Santis LP, Saladino R. Current advances in the synthesis and antitumoral activity of SIRT1-2 inhibitors by modulation of p53 and pro-apoptotic proteins. Curr Med Chem. 2012; 19:5871-84.
• [41]Iglesias RM, Spray DC. Pannexin1-mediated ATP release provides signal transmission between Neuro2A cells. Neurochem Res. 2012; 37:1355-63.
• [42]Singh PK, Chan PF, Hibbs MJ, Vazquez MJ, Segura DC, Thomas DA et al.. High-yield production and characterization of biologically active GST-tagged human topoisomerase IIα protein in insect cells for the development of a high-throughput assay. Protein Expr Purif. 2011; 76:165-72.
• [43]Alonso I, Torné A, Puig-Tintoré LM, Esteve R, Quinto L, Garcia S et al.. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. Am J Obstet Gynecol. 2007; 197:359.
• [44]Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al.. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189:12-9.
• [45]Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer. 2011; 11:9-22.
• [46]Hirshoren N, Bulvik R, Neuman T, Rubinstein AM, Meirovitz A, Elkin M. Induction of heparanase by HPV E6 oncogene in head and neck squamous cell carcinoma. J Cell Mol Med. 2014; 18:181-6.
• [47]Wang H, Mo P, Ren S, Yan C. Activating transcription factor 3 activates p53 by preventing E6-associated protein from binding to E6. J Biol Chem. 2010; 285:13201-10.
• [48]Kang KF, Wang XW, Chen XW, Kang ZJ, Zhang X, Wilbur RR et al.. Beclin 1 and nuclear factor-κBp65 are upregulated in hepatocellular carcinoma. Oncol Lett. 2013; 5:1813-8.
• [49]Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101-8.